Tenax Therapeutics' stock dropped about 84-85% after its Phase 3 LEVEL trial for TNX-103 in PH-HFpEF failed to meet primary and key secondary endpoints. The trial showed no significant improvement in patient outcomes, causing a sharp loss in shareholder value. Investors who bought TENX shares and suffered losses, whether they still hold the stock or sold at a loss, may be eligible to join a legal investigation into potential securities violations. There is no minimum loss required to participate, and no upfront cost for evaluation or involvement in the investigation.
Wall Street futures showed little movement Friday following the S&P 500's record close on Thursday, driven by softer-than-expected inflation data and reduced concerns over further Federal Reserve rate hikes. The Dow Jones futures inched up 0.1%, whil...
Meta Platforms is investing heavily in its Hyperion campus in Louisiana, with Bloomberg estimating the total cost could exceed $250 billion, though Meta has publicly confirmed spending over $50 billion. The campus will eventually support 1,000 perman...
FirstCash Holdings posted robust Q2 results with revenue up 29% and EBITDA rising 39%, driven by strong demand in U.S. and Latin American pawn operations. The company has consistently raised its guidance, maintaining strong profit margins across key ...
Solana (SOL) is stabilizing near $76, testing a key resistance zone between $80 and $85 that it must reclaim to confirm a stronger recovery. Analysts highlight layered support levels at $76.69, $67.06, and $53.33, with potential for a rebound if Bitc...
ON Semiconductor's Q2 2026 results show significant growth in AI data center revenue, more than doubling year over year, with expectations to double again in 2026. The company leads in supplying power semiconductors across AI server racks, EV powertr...
